Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.73
RDY's Cash to Debt is ranked higher than
64% of the 1152 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.37 vs. RDY: 0.73 )
RDY' s 10-Year Cash to Debt Range
Min: 0.1   Max: No Debt
Current: 0.73

Equity to Asset 0.57
RDY's Equity to Asset is ranked higher than
67% of the 1034 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.58 vs. RDY: 0.57 )
RDY' s 10-Year Equity to Asset Range
Min: 0.31   Max: 0.82
Current: 0.57

0.31
0.82
Interest Coverage 20.43
RDY's Interest Coverage is ranked higher than
58% of the 618 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 176.76 vs. RDY: 20.43 )
RDY' s 10-Year Interest Coverage Range
Min: 2.17   Max: 1038.42
Current: 20.43

2.17
1038.42
F-Score: 7
Z-Score: 6.96
M-Score: -2.36
WACC vs ROIC
2.29%
18.74%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 18.03
RDY's Operating margin (%) is ranked higher than
88% of the 1102 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.84 vs. RDY: 18.03 )
RDY' s 10-Year Operating margin (%) Range
Min: -4.08   Max: 30.47
Current: 18.03

-4.08
30.47
Net-margin (%) 15.11
RDY's Net-margin (%) is ranked higher than
89% of the 1102 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.10 vs. RDY: 15.11 )
RDY' s 10-Year Net-margin (%) Range
Min: -7.44   Max: 29.6
Current: 15.11

-7.44
29.6
ROE (%) 22.86
RDY's ROE (%) is ranked higher than
93% of the 1129 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.93 vs. RDY: 22.86 )
RDY' s 10-Year ROE (%) Range
Min: -11.56   Max: 47.58
Current: 22.86

-11.56
47.58
ROA (%) 12.49
RDY's ROA (%) is ranked higher than
92% of the 1161 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.32 vs. RDY: 12.49 )
RDY' s 10-Year ROA (%) Range
Min: -6.1   Max: 31.93
Current: 12.49

-6.1
31.93
ROC (Joel Greenblatt) (%) 29.32
RDY's ROC (Joel Greenblatt) (%) is ranked higher than
85% of the 1156 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.14 vs. RDY: 29.32 )
RDY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -9.08   Max: 121.86
Current: 29.32

-9.08
121.86
Revenue Growth (3Y)(%) 20.80
RDY's Revenue Growth (3Y)(%) is ranked higher than
89% of the 932 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. RDY: 20.80 )
RDY' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0.4   Max: 46.1
Current: 20.8

0.4
46.1
EBITDA Growth (3Y)(%) 27.10
RDY's EBITDA Growth (3Y)(%) is ranked higher than
91% of the 839 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.70 vs. RDY: 27.10 )
RDY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -37   Max: 154.4
Current: 27.1

-37
154.4
EPS Growth (3Y)(%) 24.70
RDY's EPS Growth (3Y)(%) is ranked higher than
88% of the 811 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. RDY: 24.70 )
RDY' s 10-Year EPS Growth (3Y)(%) Range
Min: -65   Max: 171.9
Current: 24.7

-65
171.9
» RDY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

RDY Guru Trades in Q1 2014

Sarah Ketterer 425,200 sh (+65.78%)
Ken Fisher 2,322,863 sh (+56.30%)
Caxton Associates Sold Out
» More
Q2 2014

RDY Guru Trades in Q2 2014

Jeremy Grantham 5,300 sh (New)
Ken Fisher 3,773,114 sh (+62.43%)
Sarah Ketterer 194,800 sh (-54.19%)
» More
Q3 2014

RDY Guru Trades in Q3 2014

Ken Fisher 3,994,868 sh (+5.88%)
Jeremy Grantham Sold Out
Sarah Ketterer 167,800 sh (-13.86%)
» More
Q4 2014

RDY Guru Trades in Q4 2014

Sarah Ketterer 603,012 sh (+259.36%)
Ken Fisher 4,153,572 sh (+3.97%)
» More
» Details

Insider Trades

Latest Guru Trades with RDY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 27.40
RDY's P/E(ttm) is ranked higher than
84% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 64.60 vs. RDY: 27.40 )
RDY' s 10-Year P/E(ttm) Range
Min: 10.33   Max: 430.4
Current: 27.4

10.33
430.4
Forward P/E 22.37
RDY's Forward P/E is ranked higher than
83% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. RDY: 22.37 )
N/A
PE(NRI) 27.90
RDY's PE(NRI) is ranked higher than
86% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 61.40 vs. RDY: 27.90 )
RDY' s 10-Year PE(NRI) Range
Min: 10.33   Max: 429.17
Current: 27.9

10.33
429.17
P/B 5.60
RDY's P/B is ranked higher than
57% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.13 vs. RDY: 5.60 )
RDY' s 10-Year P/B Range
Min: 1.27   Max: 11.54
Current: 5.6

1.27
11.54
P/S 4.14
RDY's P/S is ranked higher than
59% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.19 vs. RDY: 4.14 )
RDY' s 10-Year P/S Range
Min: 0.94   Max: 10.59
Current: 4.14

0.94
10.59
PFCF 72.20
RDY's PFCF is ranked higher than
76% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. RDY: 72.20 )
RDY' s 10-Year PFCF Range
Min: 9.89   Max: 316.29
Current: 72.2

9.89
316.29
POCF 26.56
RDY's POCF is ranked higher than
82% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 45.91 vs. RDY: 26.56 )
RDY' s 10-Year POCF Range
Min: 6.81   Max: 332.21
Current: 26.56

6.81
332.21
EV-to-EBIT 24.32
RDY's EV-to-EBIT is ranked higher than
83% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 43.18 vs. RDY: 24.32 )
RDY' s 10-Year EV-to-EBIT Range
Min: -7942.7   Max: 1600.9
Current: 24.32

-7942.7
1600.9
PEG 0.35
RDY's PEG is ranked higher than
99% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. RDY: 0.35 )
RDY' s 10-Year PEG Range
Min: 0.25   Max: 1.97
Current: 0.35

0.25
1.97
Shiller P/E 49.70
RDY's Shiller P/E is ranked higher than
84% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. RDY: 49.70 )
RDY' s 10-Year Shiller P/E Range
Min: 16.16   Max: 116.27
Current: 49.7

16.16
116.27
Current Ratio 1.91
RDY's Current Ratio is ranked higher than
67% of the 1100 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.13 vs. RDY: 1.91 )
RDY' s 10-Year Current Ratio Range
Min: 1.04   Max: 5.29
Current: 1.91

1.04
5.29
Quick Ratio 1.41
RDY's Quick Ratio is ranked higher than
68% of the 1100 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.60 vs. RDY: 1.41 )
RDY' s 10-Year Quick Ratio Range
Min: 0.68   Max: 4.3
Current: 1.41

0.68
4.3
Days Inventory 158.42
RDY's Days Inventory is ranked higher than
68% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 148.81 vs. RDY: 158.42 )
RDY' s 10-Year Days Inventory Range
Min: 77.02   Max: 156
Current: 158.42

77.02
156
Days Sales Outstanding 104.03
RDY's Days Sales Outstanding is ranked higher than
68% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 89.68 vs. RDY: 104.03 )
RDY' s 10-Year Days Sales Outstanding Range
Min: 42.16   Max: 100.37
Current: 104.03

42.16
100.37

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.52
RDY's Dividend Yield is ranked lower than
74% of the 681 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.30 vs. RDY: 0.52 )
RDY' s 10-Year Dividend Yield Range
Min: 0.46   Max: 0.97
Current: 0.52

0.46
0.97
Dividend Payout 0.14
RDY's Dividend Payout is ranked higher than
95% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. RDY: 0.14 )
RDY' s 10-Year Dividend Payout Range
Min: 0.37   Max: 0.91
Current: 0.14

0.37
0.91
Dividend growth (3y) 10.10
RDY's Dividend growth (3y) is ranked higher than
78% of the 481 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.80 vs. RDY: 10.10 )
RDY' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 44.2
Current: 10.1

0
44.2
Yield on cost (5-Year) 1.89
RDY's Yield on cost (5-Year) is ranked higher than
61% of the 688 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.53 vs. RDY: 1.89 )
RDY' s 10-Year Yield on cost (5-Year) Range
Min: 1.73   Max: 3.66
Current: 1.89

1.73
3.66
Share Buyback Rate -0.10
RDY's Share Buyback Rate is ranked higher than
87% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -1.60 vs. RDY: -0.10 )
RDY' s 10-Year Share Buyback Rate Range
Min: -0.1   Max: -6.6
Current: -0.1

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 6.80
RDY's Price/Tangible Book is ranked higher than
62% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. RDY: 6.80 )
RDY' s 10-Year Price/Tangible Book Range
Min: 4.14   Max: 79.69
Current: 6.8

4.14
79.69
Price/DCF (Projected) 3.60
RDY's Price/DCF (Projected) is ranked higher than
84% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. RDY: 3.60 )
RDY' s 10-Year Price/DCF (Projected) Range
Min: 1.47   Max: 4.58
Current: 3.6

1.47
4.58
Price/Median PS Value 1.30
RDY's Price/Median PS Value is ranked higher than
79% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.60 vs. RDY: 1.30 )
RDY' s 10-Year Price/Median PS Value Range
Min: 0.38   Max: 3.53
Current: 1.3

0.38
3.53
Price/Peter Lynch Fair Value 1.10
RDY's Price/Peter Lynch Fair Value is ranked higher than
97% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. RDY: 1.10 )
RDY' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.48   Max: 1.97
Current: 1.1

0.48
1.97
Price/Graham Number 2.90
RDY's Price/Graham Number is ranked higher than
81% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.40 vs. RDY: 2.90 )
RDY' s 10-Year Price/Graham Number Range
Min: 1.85   Max: 10.86
Current: 2.9

1.85
10.86
Earnings Yield (Greenblatt) 4.10
RDY's Earnings Yield (Greenblatt) is ranked higher than
79% of the 1148 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. RDY: 4.10 )
RDY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 10.2
Current: 4.1

0.1
10.2
Forward Rate of Return (Yacktman) 44.29
RDY's Forward Rate of Return (Yacktman) is ranked higher than
97% of the 576 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.03 vs. RDY: 44.29 )
RDY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -9.4   Max: 47.3
Current: 44.29

-9.4
47.3

Analyst Estimate

Mar15 Mar16
Revenue(Mil) 2,382 2,667
EPS($) 2.12 2.50
EPS without NRI($) 2.12 2.50

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:RDDA.Germany, 500124.India, DRREDDY.India,
Dr Reddy Laboratories Ltd was incorporated in India as a Private Limited Company on February 24, 1984. The Company converted to a Public Limited Company on December 6, 1985. The Company together with its subsidiaries is an India-based pharmaceutical company engaged in manufacturing of pharmaceutical products. The Company operates through three segments; Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products. The Company offers a portfolio of products and services, including Active Pharmaceutical Ingredients ("APIs"), Custom Pharmaceutical Services ("CPS"), generics, biosimilars, differentiated formulations and New Chemical Entities ("NCEs"). The Global Generics segment consists of finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). This segment includes the operations of the Company's biologics business. The Pharmaceutical Services and Active Ingredients segment includes active pharmaceutical ingredients and intermediaries, also known as active pharmaceutical products or bulk drugs, which are the principal ingredients for finished pharmaceutical products. Active pharmaceutical ingredients and intermediaries become finished pharmaceutical products when the dosages are fixed in a form ready for human consumption such as a tablet, capsule or liquid using additional inactive ingredients. This segment also includes contract research services and the manufacture and sale of active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment includes the discovery and development of new chemical entities and differentiated formulations for subsequent commercialization. The Company's differentiated formulations portfolio consists of new, synergistic combinations and technologies that improve safety and/or efficacy by modifying pharmacokinetics of existing medicines. This segment also includes the Company's specialty pharmaceuticals business, which conducts sales and marketing operations for in-licensed and co-developed dermatology products. The Company's products includes; Zoledronic acid, Azacitidine, Moxifloxacin, Decitabine, Donepezil 23 mg, and Sumatriptan Auto Injector. The Company's competitors include Cipla Limited, GlaxoSmithKline Pharmaceuticals Limited, Cadila Healthcare Limited, Sun Pharmaceutical Industries Limited, Alkem Limited, Pfizer Limited, Abbott India, Lupin Limited, Aristo Pharma Limited, Intas Pharma, Sanofi India Limited, Emcure Pharmaceuticals Limited. Berlin Chemi AG, Gedeon Richter Limited, Krka d.d., Teva Pharmaceutical Industries Ltd., Ranbaxy Laboratories Limited, Nycomed International Management GmbH and Zentiva N.V. The Company's manufacturing and marketing of drugs, drug products and cosmetics is governed by many statutes, regulations and guide
» More Articles for RDY

Headlines

Articles On GuruFocus.com
Emerging Market Stocks To Watch Out For Feb 17 2015 
Should You Buy Actavis? Mar 18 2014 
Dr. Reddy’s Laboratories: Should Continue to Gain Market Share in Lucrative Markets May 25 2012 
5 Mid-Cap Healthcare Dividend Stocks with Perfect Earnings Growth Dec 05 2011 
Abbott Laboratories and the “India Cure” for the Ailing Pharmaceutical Industry May 26 2010 
Dr. Reddy’s Q3 FY09 Revenue at Rs. 18,401 million, EBITDA at Rs. 3,453 million, PAT at Rs. 1,924 m Jan 20 2009 


More From Other Websites
3 Large-Cap Pharmaceutical Companies to Invest in Right Now Apr 22 2015
Curis Presents Preclinical Data on CUDC-427 at AACR Annual Meeting Apr 22 2015
Curis Presents Preclinical Data on CUDC-427 at AACR Annual Meeting Apr 22 2015
Curis Announces Presentation of Data from CUDC-427 and IRAK-4 Programs at AACR Annual Meeting Apr 16 2015
Curis Announces Presentation of Data From CUDC-427 and IRAK-4 Programs at AACR Annual Meeting Apr 14 2015
Dr Reddy's sees India sales growing 20 percent on new product launches Apr 10 2015
Dr Reddy's sees India sales growing 20 percent on new product launches Apr 10 2015
Dr. Reddy’s Laboratories and Its Subsidiary Promius PharmaTM Announce the Filing of Three NDAs... Apr 07 2015
Dr. Reddy’s Laboratories and Its Subsidiary Promius PharmaTM Announce the Filing of Three NDAs... Apr 07 2015
Taxus Cardium Announces Agreement With Dr. Reddy's Laboratories To Co-Develop, Market & Sell Generx... Apr 07 2015
Taxus Cardium Announces Agreement With Dr. Reddy's Laboratories To Co-Develop, Market & Sell Generx... Apr 07 2015
UCB to Sell Indian Established Brands Portfolio to Dr. Reddy's - Analyst Blog Apr 02 2015
Sensex rises over 1 percent, posts first weekly gain in four Apr 01 2015
Sensex rises over 1 percent, posts first weekly gain in four Apr 01 2015
Dr. Reddy’s Laboratories to Acquire Select Portfolio of the Established Products Business of UCB... Apr 01 2015
Dr. Reddy’s Laboratories to Acquire Select Portfolio of the Established Products Business of UCB... Apr 01 2015
Dr Reddy's to buy some UCB brands for $128 million Apr 01 2015
Dr Reddy's to buy some UCB brands for $128 million Apr 01 2015
India Headlines: Sensex Crashes; Rupee Falls; Ford To Triple Exports Mar 26 2015
India Headlines: GDP Growth of 7.8%, Foreign Investment Peaking? Mar 24 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK